glp 1 and aging GLP-1 Drugs & What They Do Beyond GLP‐1s: The blueprint for

Metabolic messengers: Glucagonlike peptide 1

The following information can be used to inform adjustment of background therapies in a patient starting a GLP-1 RA, with the approach individualized based on the specific needs of each patient

Many lawsuits center around Ozempic patients who have suffered gastroparesis, a serious condition involving the paralysis of the stomach and intestinal blockages

TRANSCEND-T2D-1 (NCT06354660) will compare the efficacy and safety of retatrutide compared to placebo in people with inadequately controlled T2D treated with diet and exercise over a period of 11 months

The GLP-1 market is forecast to increase at 6.1% compound annual growth rate from 2021 to 2028, from a starting point of US$12.7 billion (10.0 billion) in annual sales.(2) This projection may be conservative if GLP-1s are approved for additional indications, such as reduction of cardiovascular disease